BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 11, 2024
See today's BioWorld
Home
» NeurogesX Reports Positive Phase III Study Of NGX-4010
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
NeurogesX Reports Positive Phase III Study Of NGX-4010
Sep. 5, 2007
By
Jim Shrine
No Comments
NeurogesX Inc. reported the pain patch NGX-4010 met primary and secondary endpoints in a third Phase III trial, and the second in patients with postherpetic neuralgia. (BioWorld Today)
BioWorld
